MétaCan
Menu
Back to cohort
Record W3119730599 · doi:10.1158/1078-0432.ccr-20-3241

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

2021· article· en· W3119730599 on OpenAlexaff
Helen X. Chen, Minkyung Song, Holden T. Maecker, Sacha Gnjatic, David R. Patton, J. Jack Lee, Stacey J. Adam, Radim Moravec, Xiaole Shirley Liu, Ethan Cerami, James Lindsay, Ming Tang, F. Stephen Hodi, Catherine J. Wu, Ignacio I. Wistuba, Gheath Alatrash, Chantale Bernatchez, Sean C. Bendall, Stephen M. Hewitt, Elad Sharon, Howard Streicher, Rebecca A. Enos, Melissa Bowman, Valérie Tatard-Leitman, Beatriz Sánchez‐Espiridión, Srinika Ranasinghe, Mina Pichavant, Diane M. Del Valle, Joyce E. Yu, Sylvie Janssens, Jenny Peterson-Klaus, Cathy Rowe, Gerold Bongers, Robert R. Jenq, Chia‐Chi Chang, Jeffrey S. Abrams, Margaret Mooney, James H. Doroshow, Lyndsay N. Harris, Magdalena Thurin

Bibliographic record

VenueClinical Cancer Research · 2021
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsInstitute of Infection and Immunity
FundersNational Cancer InstituteDana-Farber Cancer InstituteUniversity of Texas MD Anderson Cancer CenterStanford UniversityLanguage Literacy and Culture, University of Maryland, Baltimore County
KeywordsCancerBiomarkerClinical trialMedicineHarmonizationCancer immunotherapyCancer biomarkersImmunotherapyOncologyComputational biologyInternal medicineBiology

Abstract

fetched live from OpenAlex

PURPOSE: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immuno-oncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. EXPERIMENTAL DESIGN: Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH. RESULTS: The CIMAC-CIDC Network is composed of four academic centers with multidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data. CONCLUSIONS: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: whole-exome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.052
metaresearch head score (Gemma)0.050
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.052
Threshold uncertainty score0.276

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0520.050
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0060.007
Science and technology studies0.0020.002
Scholarly communication0.0070.005
Open science0.0060.013
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0370.020

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.368
GPT teacher head0.542
Teacher spread0.174 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations31
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207